Loading patent…
OwnerRichard Bucala, Lin Leng +1inventors
InventorsRichard Bucala, Lin Leng, Sarah Doernberg
Estimating the term…
The present invention relates to methods and compositions for selecting a subject for treatment with an agonist or antagonist of macrophage migration inhibitory factor (MIF), identifying a subject at risk for developing a disease associated with high or low MIF expression, predicting the severity of a disease associated with high or low MIF expression in a subject, and for predicting whether a subject is susceptible to a disease associated with high or low MIF expression. The invention also provides novel methods of diagnosing a patient for a disease associated with high or low MIF expression. Also provided are methods for treating a subject having a disease or disorder associated with high or low MIF expression.
-93. (canceled)
A method of genotyping a subject for the presence of a polymorphism associated with MIF expression, the method comprising detecting or measuring the presence of guanine (G) or cytosine (C) at position −173 of the MIF promoter, wherein C at position −173 is associated with high MIF expression and G at position −173 is associated with low MIF expression.
A solid substrate for simultaneously genotyping a microsatellite repeat and a SNP, comprising at least two polynucleotide probes that are complementary to one or more polymorphic regions of the MIF gene wherein at least one of the probes detects a microsatellite repeat and at least one of the probes detects a SNP, wherein at least one of the probes hybridizes specifically to a guanine or a cytosine in the −173 region of the MIF promoter.
A method of treating anemia of chromic disease comprising administering to a subject in need thereof a therapeutically effective amount of a MIF antagonist.
A method of treating malaria comprising administering to a subject in need thereof a therapeutically effective amount of a MIF antagonist.
A method of treating an infection comprising administering to a subject in need thereof a therapeutically effective amount of a MIF agonist.
A method of attenuating the biological function of MIF, comprising the use of an agent that inhibits the interaction between CD44 and CD74.
A method of attenuating the biological function of MIF, comprising the use of an agent that inhibits the expression of CD44.
A method of increasing the biological function of MIF, comprising the use of an agent that increases the interaction between MIF, CD44 and CD74.
A method of increasing the biological function of MIF, comprising the use of an agent that increases the interaction between CD44 and CD74.
A method of identifying potential agonists or antagonists of MIF, comprising:
A method of identifying potential agonists or antagonists of MIF, comprising:
A kit comprising:
A kit comprising:
Dependencies are inferred from the claim text.